Loading…
Further Extension of Continuing Appropriations Act, 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
100pct
658d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Purple Book Continuity Act of 2019 This bill modifies requirements for the Food and Drug Administration to publish information regarding biological products.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (78)
Became Public Law No: 116-246.
Became Public Law No: 116-246.
Signed by President.
Signed by President.
Presented to President.
Presented to President.
Message on Senate action sent to the House.
Senate agreed to the House amendment to the Senate amendment to H.R. 1520 by Voice Vote. (consideration: CR S7923)
Resolving differences -- Senate actions: Senate agreed to the House amendment to the Senate amendment to H.R. 1520 by Voice Vote.
Message on House action received in Senate and at desk: House amendment to Senate amendment.
House agreed to the Senate amendment with an amendment pursuant to the provisions of H.Res. 1271. (consideration: CR H7300; text of amendment in the nature of a substitute: CR H7300)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2020 · fourth_quarter · Budget/Appropriations
H.R. 133 - FY2021 Omnibus and COVID Relief and Response Act, including S.Amdt.2731 - housing H.R. 1520 - FY2021 Continuing Appropriations Act H.R. 7617 - Defense, Commerce, Justice, Science, Energy and Water Development, Financial Services and General Government, Labor, Health and Human Services, Education, Transportation, Housing, and Urban Development Appropriations Act, 2021 - insurance H.R. 7668 - Financial Services and General Government Appropriations Act, 2021 - insurance H.R. 7669 - Department of Homeland Security Appropriations Act, 2021 - disaster mitigation funding H.R. 8900 - FY2021 Further Continuing Appropriations Act and Other Extensions Act H.J.Res.107 - FY2021 Continuing Appropriations Act H.J.Res.110 - FY2021 Continuing Appropriations Act Risk transfer legislation Senate fiscal year 2021 Department of Homeland Security appropriations - disaster mitigation funding Senate fiscal year 2021 financial services and general government appropriations - insurance
Client expense: $280,000 · Firm income: Not reported
Government targets: Export-Import Bank of the United States (EXIM Bank), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
2020 · second_quarter · Health Issues
Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)
2020 · fourth_quarter · Health Issues
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act (HCR) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Ac - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
Client expense: $2,030,000 · Firm income: Not reported
2020 · fourth_quarter · Copyright/Patent/Trademark
S. 1224, Stop STALLING Act S. 1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 3991-Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133--Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 1503 - the Orange Book Transparency Act; and H.R. 1520 - Orange Book Transparency Act of 2019; H.R. 3 - Lower Drug Costs Now Act of 2019 - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Client expense: $2,030,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2020 · fourth_quarter · Medicare/Medicaid
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
Client expense: $2,030,000 · Firm income: Not reported
Message on Senate action sent to the House.
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S7396-7397)
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S7396-7397)
Measure laid before Senate by unanimous consent. (consideration: CR S7396-7397)
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by recorded vote (2/3 required): 421 - 0 (Roll no. 188). (text: CR H3485-3486)
HousePassed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by recorded vote (2/3 required): 421 - 0 (Roll no. 188).(text: CR H3485-3486)
HouseConsidered as unfinished business. (consideration: CR H3491-3492)
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Ms. Eshoo objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
DEBATE - The House proceeded with forty minutes of debate on H.R. 1520.
Considered under suspension of the rules. (consideration: CR H3485-3486)
Ms. Eshoo moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 26.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-48.
Congress.gov source codes: 5000, H12200
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Subcommittee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| House |
| Markup by |
| April 3, 2019 |
| Energy and Commerce Committee | House | Referred to | March 5, 2019 |
| May 9, 2019 |
| Engrossed in House | May 8, 2019 |
| Reported in House | May 3, 2019 |
| Introduced in House | March 5, 2019 |
| Enrolled Bill | -- |
| Democratic |
| FL |
| Doris O. Matsui | Democratic | CA |
| Frank Pallone, Jr. | Democratic | NJ |
| Greg Walden | Republican | OR |
| Jefferson Van Drew | Republican | NJ |
| Joseph P. Kennedy III | Democratic | MA |
| Michael C. Burgess | Republican | TX |
| Raul Ruiz | Democratic | CA |
| Yvette D. Clarke | Democratic | NY |
| HJRES 107 |
116th |
| Related bill |
| HCONRES 128 | 116th | Related bill |
Client expense: $540,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2020 · third_quarter · Health Issues
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency
Client expense: $2,750,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2020 · third_quarter · Medicare/Medicaid
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation -Issues related to the International Pricing Index for Medicare Part B -Issues related to CMMI
Client expense: $2,750,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2020 · second_quarter · Health Issues
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency Medical Supply Chain - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
Client expense: $1,930,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2020 · second_quarter · Medicare/Medicaid
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
Client expense: $1,930,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2020 · first_quarter · Health Issues
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency
Client expense: $2,790,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2020 · first_quarter · Medicare/Medicaid
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
Client expense: $2,790,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2020 · fourth_quarter · Health Issues
Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)
Client expense: $830,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · third_quarter · Health Issues
Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)
Client expense: $810,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Health Issues
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
Client expense: $1,600,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · second_quarter · Health Issues
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
Client expense: $2,160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · fourth_quarter · Budget/Appropriations
FY 2021 Budget Resolution - lobbied against the Presidents FY 2021 budget. Lobbied against negative impact on federal employees' compensation and benefits including requiring employees to pay additional salary towards retirement. Lobbied against privatizing of airport screening jobs. FY 2021 Homeland Security Appropriations--Lobbied in support for additional funding of Customs and Border Protection (CBP), Immigration and Customs Enforcement (ICE), Citizenship and Immigration Services (CIS), Federal Emergency Management Agency (FEMA), Coast Guard (USCG), Federal Protective Service (FPS), and Transportation Security Administration (TSA). Specifically, lobbied for retention of prohibitions against the OMB Circular A-76 process in the Coast Guard's National Vessel Documentation Center (NVDC) and on certain positions in CIS related to investigating and adjudicating immigration rights benefits. Lobbied for funding to restore health insurance for part-time Transportation Security Officers and to restore cleaning of checkpoint lanes at airports. FY 2021 Defense Appropriations -- Lobbied in support of limitations on use of appropriated funds for service contracts unless their planning, programming and budgeting is in compliance with section 2329 of title 10 and related total force management statutes. House directive report language. FY 2021 Military Quality of Life/Veterans Affairs Appropriations--Lobbied in support for funding to hire new employees to fill vacancies; provisions to provide adequate funding for VA health and benefits programs and against further contracting out. Lobbied for the inclusion of language to prevent unilateral implementation of collective bargaining agreements. FY 2021 Interior and Environment Appropriations - Lobbied for adequate funding of EPA, National Endowment for the Arts and Humanities, issues related to contracting out, pay, and working conditions of federal employee jobs and proposed EPA spending cuts. FY 2021 Labor-HHS-Education Appropriations-Lobbied on contracting out, funding cuts to services such as college aid for students, rural health care services, and funding the National Institutes of Health (NIH), and status of collective bargaining. Lobbied against Administration proposal to close and transfer Forest Service Job Corps Civilian Conservation Centers. Lobbied for increased Social Security Administration funding and status of collective bargaining. Lobbied to restore adequate funding to the Social Security Administration. Lobbied for an amendment to defund the EEOC official time proposed rule. Lobbied in support of blocking the EEOC official time proposed rule from being finalized in the federal register and lobbied in support of blocking the final rule in the Congressional Review Act in the 117th Congress. FY 2021 Financial Services and General Government Appropriations--Lobbied for full funding for the Office of Personnel Management (OPM) and to prohibit any funds from being spent to merge OPM with the General Services Administration (GSA) or Office of Management and Budget (OMB). FY 2021 Commerce-Justice-Science Appropriations--Lobbied for higher funding levels for Bureau of Prisons (BOP) and continued prohibition of closure of minimum security camps; lobbied for funding to hire adequate numbers of correctional staff; end the use of augmentation to compensate for lack of hiring correctional officer positions; alleviating overcrowding at high-security institutions; need to increase unit officer staff at high security institutions; and reduce the use of BOP contract prisons. FY 2021 Transportation, Housing and Urban Development (THUD) Appropriations--Lobbied on contracting out, pay, benefits, and working conditions of federal employees. FY 2021 Agriculture Appropriations-Lobbied against provisions on contracting out of federal employee jobs and funding cuts to the Food Safety and Inspection Service. Lobbied against creation of a modernized beef slaughter inspection system or issue line speed waivers to beef slaughter plants. FY 2021 Energy and Water Appropriations - Lobbied against any cuts in funding for fossil fuel research conducted at the National Energy Technology Laboratories (NETL). Lobbied against any limitation or elimination of official time to all appropriations bills. Lobbied for prohibition of realigning the Army Civilian Works program from Corps of engineers to Department of transportation and Department of Interior. Lobbied in support of the "Recognizing the Environmental Gains in Overcoming Negligence Act" (REGION Act) to ensure that no EPA office be closed, consolidated, or eliminated using funds made available in any appropriations act for any fiscal year. Lobbied in support of H.R. 5885/S. 3104, the "Federal Employee Parental Leave Technical Correction Act." Lobbied for higher funding levels for the United States Census Bureau, American Community Survey, Economic Survey, and Bureau of Labor Statistics relocation FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Natural Resources
FY 2021 Interior and Environmental Appropriations--lobbied on provisions relating to the pay, benefits, staffing levels, job security, and contracting out of Department of Interior (DOI) employees. Lobbied against reopening of EPA offices without adequate health and safety protocols. FY 2021 Energy and Water Appropriations--Lobbied against any cuts in funding for fossil fuel research conducted at the National Energy Technology Laboratories (NETL). FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Homeland Security
FY 2021 Homeland Security Appropriations--lobbied on provisions on the pay, benefits, contracting out, staffing levels, funding, and job security of DHS employees in CIS, ICE, CIS, FEMA, FPS, USCG, and TSA. Lobbied on issues surrounding safe workplaces under the coronavirus pandemic and standards for reopening of all agencies within Homeland Security. Lobbied in support of S. 944, the "Strengthening American Transportation Security Act," which would grant Transportation Security Officers (TSOs) rights under Title 5 of the U.S. code and H.R. 1140, the Rights for TSA Officers Act and for inclusion of H.R. 1140 as passed in the House into H.R. 2, the INVEST Act and for passage of H.R. 2. Lobbied in support of H.R. 372, the "Honoring Our Fallen TSA Heroes Act," ensuring public safety officer benefits to TSOs killed or injured in the line of duty. Lobbied for restoring the full-time health care subsidy for new part-time TSOs. Lobbied against transferring airport exit lane monitoring responsibilities to airports. Lobbied against S. 3730 which allows for the privatization of airport ID checks and allowing private companies to determine whether a passenger is subject to secondary screening. Lobbied in support of increased funding for TSO compensation and effects of pandemic related pay cuts. Lobbied in support of collective bargaining protections. Briefed Homeland Security staff and chair on the status of the collective bargaining agreement ratification for TSA employees and sought the Chairmans outreach to the agency regarding its sudden and ill-timed decision to restart the ratification process. Lobbied on proposed Air Travel Task Force legislation for inclusion of the unionized workforce view in decision-making. Lobbied on S. 4623, the Fly Safe and Healthy Act to make improvements to legislation requiring TSA to develop pilot programs to check the temperatures of individuals passing through screening checkpoints. Lobbied in support of H.R. 1433, the "DHS MORALE Act" to address workforce morale at the Department of Homeland Security (DHS). Lobbied in support of H.R. 1171/S. 472, the "Funding for Aviation Screeners and Threat Elimination Restoration (FASTER) Act," to amend title 49, United States Code, to ensure that revenues collected from passengers as aviation security fees are used to help finance the costs of aviation security screening by repealing a requirement that a portion of such fees be credited as offsetting receipts and deposited in the general fund of the Treasury. Lobbied against Ready Reserve Corps in the Public Health Service. Lobbied in support of H.R. 4020 the "Checkpoint Safety Act," to require armed law enforcement at checkpoints in large airports. Lobbied for more PPE for TSOs, for requiring passengers to wear masks and on the notion of TSOs doing temperature screenings at checkpoints. Lobbied in support of H.R. 6647, the "Health Care Opportunities for Transportation Security Administration Employees Act." Lobbied in support of H.R. 6655, the "Hazardous Duty Pay for Frontline Federal Workers Act." Lobbied in support of H.R. 6656, the "Coronavirus Workers' Compensation for TSA Employees Act." Lobbied in support of USCIS employees and to oppose any further threat of furlough of thousands and agency employees. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Health Issues
Lobbied to increase the federal government's share of health benefits for its employees and retirees. Lobbied against proposal to increase Federal Employee Health Benefits Program (FEHBP)employee premiums. Lobbied in support of H.R. 748 the "Middle Class Health Benefits Tax Repeal Act of 2019." FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Foreign Relations
FY 2021 Foreign Operations Appropriations--lobbied on the provisions related to the pay, benefits, staffing levels, and job security of Department of State employees. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Defense
Lobbied in support of passage and veto override of the Fiscal Year 2021 National Defense Authorization Act. Lobbied in support of the inclusion of Section 1106 of the House-passed bill, Limiting the number of local wage areas defined within a pay locality." Lobbied in support of the inclusion of Section 1101 of the House-passed bill, Paid parental leave technical corrections, which was included in Section 1103 of the final bill. Lobbied in support of the inclusion of Section 911 of the House-passed bill, Limitation on reduction of civilian workforce, and against cuts made to Defense Agencies and Field Activities. Lobbied in support of the inclusion of the Sections 1121 through 1128 of the House-passed bill, Elijah E. Cummings Federal Employee Antidiscrimination Act of 2020," in the FY 2021 NDAA. Lobbied in support of the inclusion of the COVID-19 Emergency Medical Supplies Enhancement, in FY 2021 NDAA. Lobbied in support of federal employee leave carry over during the COVID-19 pandemic. Lobbied in the FY 2021 NDAA: Section 714, Extension of organization requirements for Defense Health Agency, Section 715, Modification to limitation on the realignment or reduction of military manning end strength, Section 716, Modifications to implementation plan for restructure or realignment of military medical treatment facilities, and Section 722, COVID-19 global war on pandemics. Lobbied in support the House-passed bill FY 2021 NDAA, Updated business case analysis on consolidation of Defense Resale System. Lobbied in support of the Senate-passed bill FY 2021 NDAA, Prohibition on conducting additional BRAC. Lobbied in support of House-passed bill FY 2021 NDAA, Documentation pertaining to commercial items determinations, and Commercial product determination applies to components and support services. Lobbied against the expansion of direct hire provisions in the FY 2021 NDAA. Lobbied in support of clarification FY 2021 NDAA, Enhancement of public-private talent exchange programs in the Department of Defense. Lobbied to exclude or clarify Section 9401 of the Senate-passed bill, Exclusivity, consistency, and transparency in security clearance procedures, and right to appeal. Lobbied for the exclusion of Section 373 of the Senate-passed bill FY 2021 NDAA, Provision of protection to the National Museum of the Marine Corps, the National Museum of the United States Army, the National Museum of the United States Navy, and the National Museum of the United States Air Force. Lobbied in support of exclusion Section 937 of the Senate-passed bill FY 2021 NDAA, Applicability to Other Provisions of Law. Lobbied in support of the exclusion of Section 946 of the Senate-passed bill FY 2021 NDAA, "Application of acquisition demonstration project to Department of the Air Force employees assigned to acquisition positions within the Space Force. Lobbied in support of the exclusion of Section 841 from the Senate-passed bill FY 2021 NDAA, Authority to acquire innovative commercial products and services using general solicitation competitive procedures. Lobbied in support of the exclusion of Section 842 from the Senate-passed bill FY 2021 NDAA, Truth in Negotiations Act threshold for Department of Defense contracts. Followed up with Armed Services Committee staff and members on allegations of discriminatory application of medical standards as conditions of employment. Lobbied House and Senate Armed staff and members regarding a Reduction in Force at the Ireland Army Medical Clinic at Fort Knox. Lobbied on requesting Review of U.S. Transportation Command (TRANSCOM's) decision-making related to the Global Household Goods Contract. Lobbied on requesting a review regarding GAO-20-532, Defense Workforce: DoD Needs to Assess its Use of Term and Temporary Appointments. Provided advice to HASC staff on previously enacted improvements to the Department of Defense planning, programming and budgeting of services contracts and examining the practice of their effect on civilian jobs. Lobbied for passage of Defense Appropriations for Fiscal Year 2021 in the final Omnibus funding for FY 2021 including prohibiting to DoD and civilian workforce personnel caps, misuse of term or temporary hiring authorities, and addressing chapter 71 and title 5 exceptions DOD. Lobbied on the Financial Services General Government Appropriation for Fiscal Year 2021 to include section 741 carryover provision that prohibits public-private competitions pursuant to OMB Circular A-76. Lobbied in support of prohibiting use of appropriated funds to implement the executive order that would allow conversion of federal employees to Schedule F. In the FY 2021 NDAA lobbied on: Section 338. "Guaranteeing Equipment Safety for Firefighters Act of 2020." There are additionally various PFAS-related sections starting from Section 335. Section 588. "24-Hour Child Care." This section authorizes the SecDef to furnish childcare to each child of a member of the Armed Forces or civilian employee of the Department of Defense while that member or employee works on rotating shifts at a military installation. Section 631. "Base responders essential needs and dining access." Section 632. "First responder access to mobile exchanges." Section 642. "Permanent authority for and enhancement of the Government lodging program." Section 702. "Waiver of fees charged to certain civilians for emergency medical treatment provided at military medical treatment facilities." Section 901. "Repeal of position of Chief Management Officer of the Department of Defense." Section 914. "Limitation on consolidation or transition to alternative content delivery methods within the Defense Media Activity." Section 1101. "Department of Defense policy on unclassified workspaces and job functions of personnel with pending security clearances." Section 1104. "Authority to provide travel and transportation allowances in connection with transfer ceremonies of certain civilian employees who die overseas." Section 1105. "One-year extension of authority to waive annual limitation on premium pay and aggregate limitation on pay for Federal civilian employees working overseas." Section 1106. "One-year extension of temporary authority to grant allowances, benefits, and gratuities to civilian employees on official duty in a combat zone." Section 1109. "Fire fighters alternative work schedule demonstration project for the Navy Mid-Atlantic Fire and Emergency Services." Section 1110. "Special rules for certain monthly workers compensation payments and other payments." "Title XVIII-Transfer and Reorganization of Defense Acquisition Statutes." Sections 1801-1885. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Labor Issues/Antitrust/Workplace
Lobbied on the confirmations of Chad Bungard, Dennis Dean Kirk, and Julia Clark to serve on the MSPB. Lobbied against confirmation of Catherine Bird to be General Counsel of FLRA. Lobbied against confirmation of John Gibbs to be director of the Office of Personnel Management. Lobbied against any attempts the expand the Department of Veterans Affairs' Accountability and Whistleblower Protection Act government-wide. Lobbied in support of H.R. 1254, the "Equal COLA Act," to achieve parity between the cost of living adjustment to an annuity under the Federal Employees Retirement System and an annuity under the Civil Service Retirement System. Lobbied in support of S. 165, the "Federal Unemployment Compensation Equality Act of 2019," to amend current law to clarify that Federal employees excepted from a furlough are eligible for unemployment compensation. Lobbied in support of S. 222, to require payment of interest on back pay for employees affected by a lapse in appropriations. Lobbied in support of H.R. 953, to help prevent negative credit reporting due to a government shutdown. Lobbied in support of S. 464, Protecting Employees' Security Clearances Act (PESCA), which requires consideration of a lapse in appropriations as a mitigating condition when assessing financial consideration for security clearances. Lobbied in support of H.R. 5690/S. 3231, the "Federal Adjustment of Income Rates Act" to provide federal employees with a 3.5% salary adjustment in 2021. Lobbied in support of S. 521 and H.R. 141, Social Security Fairness Act, to repeal the government pension offset and windfall elimination provisions. Lobbied in support of S. 530 and H.R. 1316, the "Federal Labor-Management Partnership Act," to establish the Federal Labor-Management Partnership Council. Lobbied in support of S. 24, Government Employee Fair Treatment Act of 2019, so employees of the federal government or a District of Columbia public employer who are furloughed or required to work during a lapse in appropriations beginning on or after December 22, 2018, to be compensated for the period of the lapse. Lobbied in support of H.R. 7, the "Paycheck Fairness Act," To amend the "Fair Labor Standards Act of 1938" to provide more effective remedies to victims of discrimination in the payment of wages on the basis of sex, and for other purposes. Lobbied against H.R. 605, Official Time Reporting Act, to require that the Office of Personnel Management submit an annual report to Congress relating to the use of official time by Federal employees. Lobbied for H.R. 1309, Workplace Violence Prevention for Health Care and Social Service Workers Act, to require DOL to address workplace violence in the health care and social service sectors Lobbied for H.R. 582, Raise the Wage Act, to increase the federal minimum wage for regular employees over a 7-year period, for tipped employees, and for newly hired employees who are less than 20 years old. Lobbied in support of H.R. 4328, the "Protecting Innocent Consumers Affected by the Shutdown Act of 2019." Lobbied Education and Labor Committee on collective bargaining contract effects on the Education workforce and Secretary's actions to alter the Department's work on student loans and civil rights enforcement. Lobbied in support of H.R. 3463/S. 1970, the "Public Service Freedom to Negotiated Act." Lobbied in support of H.R. 2474/S. 1306, the "Protecting the Right to Organize Act." Lobbied against the nomination of Keith Sonderling (R) and Andrea Lucas (R) nominees for the EEOC. Lobbied in support of Jocelyn Samuels (D) nominee for the EEOC. Lobbied for passage of H.R. 7574, the "Strengthening America's Strategic National Stockpile Act of 2020." FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Food Industry (safety, labeling, etc.)
FY 2021 Agriculture Appropriations--lobbied against the contracting out of federal employee jobs and potential food and public risks. Lobbied against funding cuts of the meat and poultry inspection program. Lobbied against further expanding the program of putting plant employees, not inspectors, in charge of quality control and contamination. Lobbied to prohibit funds from being spent to create a modernized beef slaughter inspection system or issue line speed waivers to beef slaughter plants. Lobbied against the Food Safety and Inspection Services' (FSIS) proposed rule on hog slaughter to eliminate hundreds of FSIS online inspector positions and transfer their responsibilities to rank and file hog company employees. Lobbied for language to prohibit the Department of Agriculture from implementing any performance appraisal system applicable to employees of the Department of Agriculture, other than Departmental Regulation DR 4040-430, dated February 6, 2019 expiring February 6, 2024. Lobbied for H.R. 7521 the "Safe Line Speeds in COVID-19 Act" and S. 4338 the "Safe Line Speeds During COVID-19 Act of 2020." FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Agriculture
FY 2021 Agriculture Appropriations - lobbied for provisions relating to pay, benefits, staffing levels, and job security of USDA employees. Lobbied to prohibit funds from being spent to create a modernized beef slaughter inspection system or issue line speed waivers to beef or hog slaughter plants. Lobbied for H.R. 7521 the "Safe Line Speeds in COVID-19 Act" and S. 4338 the "Safe Line Speeds During COVID-19 Act of 2020." Lobbied for language to prohibit the Department of Agriculture from implementing any performance appraisal system applicable to employees of the Department of Agriculture, other than Departmental Regulation DR 4040-430, dated February 6, 2019 expiring February 6, 2024. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Civil Rights/Civil Liberties
FY 2021 Commerce-Justice-Science Appropriations-Lobbied against proposals to compromise the Equal Employment Opportunity Commissions (EEOC) ability to protect employees from employment discrimination, including staffing cuts and contracting out. FY 2021 Commerce-Justice-Science Appropriations - Lobbied for higher funding levels for Bureau of Prisons (BOP) and continued prohibition of closure of minimum security camps; lobbied for funding to hire adequate numbers of correctional staff; end the use of augmentation to compensate for lack of hiring correctional officer positions; alleviating overcrowding at high-security institutions; need to increase unit officer staff at high security institutions; and reduce the use of BOP contract prisons. Lobbied in support of language to end augmentation of corrections workers, hire more correctional officers, and phase out the use of private prisons. Lobbied in support of H.R. 6427, the "PANDEMIC ACT" to prevent the transfer of prisoners between Bureau of Prisons (BOP) facilities during the COVID-19 pandemic. Lobbied in support of H.R. 99/S. 1508, the "Thin Blue Line Act" which would make murdering a law enforcement officer an aggravated factor in sentencing for a capital crime. Lobbied in support of H.R. 3980 and S. 2264 "Eric's Law," to require that crimes punishable death receive a unanimous jury verdict or a new jury be impaneled. Lobbied in support of H.R. 1, the "For the People Act," in particular its provision to expand the participation of eligible voters in elections and end voter suppression. Lobbied in support of H.R. 5, the "Equality Act," which prohibits discrimination based on sex, sexual orientation, and gender identity in a wide variety of areas including public accommodations and facilities, education, federal funding, employment, housing, credit, and the jury system. Lobbied for passage of H.R. 2694 the "Pregnant Workers Fairness Act." FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Immigration
FY 2021 Homeland Security Appropriations--lobbied on provisions on CPB, CIS, and ICE relating to contracting out, pay, benefits, staffing levels, safety, and job security of these DHS employees. Lobbied against further threat of furloughs of more than 70% of the U.S. Citizenship and Immigration Services (USCIS) workforce, effectively shutting down the agencys operations indefinitely. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · District of Columbia
Budget allocations involving the pay, benefits, staffing levels, and job security of DC Government employees. Lobbied in support of H.R. 1, the "For the People Act, in particular its provision in support of statehood for the District of Columbia. Lobbied in support of H.R. 51 the "Washington, D.C. Admission Act." Lobbied for a provision in H.R. 925. the "Heroes Act" to fix the fact that D.C. was treated as a territory instead of as a state in the Coronavirus Relief Fund in H.R. 748, the Coronavirus Aid, Relief and Economic Security "CARES" Act. As a result, D.C. was deprived of $755 million. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Government Issues
FY 2021 Financial Services and General Government Appropriations--Lobbied against implementation of pro-contractor revision of OMB Circular A-76, contracting out, and contractor compensation. FY 2021 Financial Services and General Government Appropriations--Lobbied for protection of blue collar pay, white collar pay, minimum wage, federal retirement systems, and union representation. FY 2021 Financial Services and General Government Appropriations--Lobbied for full funding for the Office of Personnel Management (OPM) and to prohibit any funds from being spent to merge OPM with the General Services Administration (GSA) or Office of Management and Budget (OMB). FY 2021 Financial Services and General Government Appropriations--Lobbied in support of protecting federal employee collective bargaining rights. FY 2021 Financial Services and General Government Appropriations--Lobbied in support of a 3.5% pay increase for federal workers. FY 2021 Financial Services and General Government Appropriations--Lobbied for parity with military pay increase. Lobbied in support of a technical fix to the paid parental leave provision in the FY 2020 NDAA that would ensure all federal employees have access to federal paid parental leave. Lobbied in support of H.R. 5399/S. 3015, the "Locality Pay Equity Act" to limit the number of local wage areas allowable within a General Schedule pay locality. Lobbied in support of S. 944, the "Strengthening American Transportation Security Act," which would grant Transportation Security Officers (TSOs) rights under Title 5 of the U.S. code and for inclusion of H.R. 1140, the Rights for TSA Officers Act in H.R. 2 and lobbied for passage of H.R. 2, the INVEST Act. Lobbied in support of H.R. 372, the "Honoring Our Fallen TSA Officers Act," granting public safety officer benefits to TSOs killed or injured in the line of duty. Lobbied in support of H.R. 1174/S. 1942, the "Federal Firefighters Fairness Act of 2019," to amend chapter 81 of title 5, creating a presumption that a disability or death of a federal employee in fire protection activities caused by any of certain diseases is the result of the performance of such employee's duty. Lobbied in support of H.R. 1255, the "Federal Firefighter Pay Equity Act," to provide for more accurate computation of retirement benefits for federal firefighters. Lobbied in support of S. 858, the "Protecting Military Firefighters from PFAS Act," requiring the Secretary of Defense to provide blood testing for firefighters in the Department of Defense to determine potential exposure to perfluoroalkyl and polyfluoroalkyl substances. Lobbied in support of H.R. 1195/S. 473, the "Law Enforcement Officer Equity Act," to include certain federal positions within the definition of law enforcement officer for retirement purposes. Lobbied for H.R. 748, the "Middle Class Health Benefits Tax Repeal Act of 2019," to the excise tax on employer-sponsored health care coverage for which there is an excess benefit (high-cost plans). Lobbied for H.R. 860, Social Security 2100 Act, to increase various Old Age, Survivors, and Disability Insurance (OASDI) benefits and related taxes. Lobbied to support S. 478 and H.R. 1170, Social Security Expansion Act, to enhance Social Security benefits and ensure the long-term solvency of the Social Security program. Lobbied on effects on workforce of proposed Sustainability Awareness Act. Lobbied on appointees to the Merit Systems Protection Board and Federal Labor Relations Authority. Lobbied in support of S. 2525, guaranteeing the "Equipment Safety for Firefighters Act." Lobbied in support of H.R. 582, the "Raise the Wage Act." Lobbied in support of H.R. 2474, the "Protecting the Right to Organize Act of 2019." Lobbied against H.R. 4090, the "Do Your Job Act of 2019." Lobbied in support of H.R. 3607, the "Fossil Energy Research and Development Act." Lobbied in support of H.R. 1534/S. 1174, the "Federal Employee Paid Leave Act" that would grant federal workers 12 weeks of paid FMLA. Lobbied in support of H.R. 6906 the Pandemic Heroes Compensation Act to provide compensation for injuries to any individual, or their families, who are deemed an essential worker and required to leave their home to perform services and who have become ill or died as a result of COVID-19. Lobbied in support of H.R. 6139 the COVID-19 Health Care Worker Protection Act of 2020 that would direct the Secretary of Labor to issue an emergency temporary standard that requires certain employers to develop and implement a comprehensive infectious disease exposure control plan to protect employees in the health care sectors and other employees at elevated risk from exposure to SARS- CoV-2. Lobbied in support of H.R. 6955 the Essential Worker Pandemic Compensation Act of 2020 that would amend the Public Health Service Act to authorize a program of death and hospitalization benefits for essential workers who die as a result of COVID-19 or related complications. Lobbied in support of S. 4347, the Federal Labor-Management COVID Partnership Act. Lobbied in support of a presumption of worksite illness for employees who apply for workers comp who get COVID-19. Lobbied in support of H.R. 6246, the "Protecting Collective Bargaining and Official Time for Federal Workers Act." Lobbied in support of H.R. 6909, the Pandemic Heroes Compensation Act. Lobbied in support of S. 3677/H.R. 6559, the "COVID-19 Every Worker Protection Act." Lobbied in support of introduction of the Fair and Accurate Information Reporting (FAIR) Act to assist consumers with their credit reports during pandemic job loss. Lobbied in support of H.R. 6733, the "Federal Frontline Worker Leave Protection Act." Lobbied in support of S. 3561, the "Emergency Telework Act of 2020." Lobbied in support of H.R. 2694, the Pregnant Workers Fairness Act. Lobbied in support of H.R. 8457/S. 4777, the Federal Worker Leave Fairness Act to restore leave lost by Federal employees during certain public health emergencies, and for other purposes. Lobbied in support of H.R. 7340, the Chai Suthammanont Remembrance Act to ensure that personal protective equipment and other equipment and supplies needed to fight coronavirus are provided to employees required to return to Federal offices, and for other purposes. Lobbied in support of H.R. 7496, the COVID PREPARE Act to require Federal agencies to submit plans for responding to any resurgence of COVID-19. Lobbied in support of H.R. 7524/S. 4610, the Wear Your Mask Act to require face masks in Federal facilities to prevent the transmission of SARS-CoV-2. Lobbied in support of S. 4347, the Federal Labor-Management COVID Partnership Act to establish a Coronavirus Rapid Response Federal Labor-Management Task Force, and for other purposes. Lobbied in support of H.R. 7076/S. 3855, the Coronavirus Oversight and Recovery Ethics (CORE) Act to ensure ethical and accountable use of COVID-19 relief funds, to prevent corruption and bias in the disbursement and supervision of those funds. Lobbied in support of H.R. 6373 to increase the amount available under the "Defense Production Act of 1950" to respond to the coronavirus epidemic. Lobbied in support of S. 3570 to provide for the expedited procurement of equipment needed to combat COVID-19 under the "Defense Production Act of 1950." Lobbied in support of H.R. 6398 the Frontline Health Care Workers Assistance Act to direct certain actions to procure equipment necessary to prevent, identify, and mitigate cases of COVID-19 (i.e., coronavirus disease 2019). Lobbied in support of S. 3763 the Pandemic Responder Service Award Act to provide a flexible award for front line health care workers who have responded to the COVID-19 pandemic that can be used to pay off existing student loans, to obtain further education or to establish a savings account to help workers purchase housing, save for retirement or establish a childrens savings account for their dependents. Lobbied in support of H.R. 6390/S. 3568, the Medical Supply Chain Emergency Act of 2020 directing the President to use existing authorities under the Defense Production Act of 1950 with respect to the production of ventilators, N-95 respirator masks, and specified personal protective equipment to address COVID-19. Lobbied in support of H.R. 6410 directing the President to use authority under the "Defense Production Act of 1950" to ensure an adequate supply of equipment necessary for limiting the spread of COVID-19. Lobbied in support of H.R. 6746, the Emergency Benefits for Independent Workers Program Act to require the Secretary of Labor to establish a program for providing portable benefits to eligible workers. Lobbied in support of H.R. 6442/S. 3513, the Providing Americans Insured Days of Leave Act of 2020 to provide Americans with paid sick time and paid leave so that they can address their own health needs and the health needs of their families. Lobbied in support of H.R. 933 a congressional resolution recognizing COVID-19 frontline workers. Lobbied in support of H.R. 8349 to provide hazard pay to frontline essential workers employed during the COVID-19 pandemic. Lobbied in opposition to forced suspension of withholding FICA taxes from federal employees payroll Sept.-Dec. 2020 to be repaid Jan.-Apr. 2021 and for waiving or extending the repayment plan. Lobbied for legislation to make the payroll tax deferral optional for federal employees. Provided statement for the record to the Senate Homeland Security and Governmental Affairs on its hearing, Modernizing Federal Telework: Moving Forward Using the Lessons Learned During the COVID-19 Pandemic. Lobbied against forced retirement or termination of federal employees who have been injured on the job and have had their medical treatment delayed because of COVID-19. Lobbied for lawmakers to support efforts to restart collective bargaining with Department of Education employees and provide adequate funding and oversight of the Departments mission, including protecting students civil rights and fairly and equitably provide student loans. Lobbied for emergency funding for the aviation industry to protect jobs of airline and airport workers. Lobbied for H.R. 9052, a bill to nullify the Presidents Executive Order creating Schedule F by imposing limits on excepting competitive service positions from the competitive service. Lobbied for H.R. 8687, Saving the Civil Service Act, a bill to nullify the Presidents Executive Order creating Schedule F. Lobbied for H.R. 8629 and S. 4810, Protecting Employees from Surprise Taxes Act of 2020, a bill to prohibit employers from deferring payment of payroll taxes unless affected employees provide written consent to a deferral. Lobbied against confirmation of John Gibbs to be director of the Office of Personnel Management (OPM). FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Housing
FY 2021 Transportation, Housing and Urban Development (THUD) Appropriations--lobbied on contracting out, pay, benefits, and working conditions of federal employees in the Department of Housing and Urban Development. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Veterans
Lobbied against the Veterans Benefits Administration's (VBA) decision to change standards for Veterans Service Representatives and potentially dismiss employees. Lobbied for comprehensive changes to internal VBA processes for claims, including changes to the VBA National Work Queue. Lobbied against contracting out of Compensation and Pension Exam positions. Lobbied against H.R. 7287/S. 4365, A bill to clarify licensure requirements for contractor medical professionals to perform medical disability examinations for the Department of Veterans Affairs, and for other purposes. Lobbied for changes to S. 4511, Veteran Benefits Enhancement and Expansion Act of 2020. Lobbied against the severe reduction of "excluded time" proposed by the VA in the "#bestyearever" plan. Lobbied on the processing of complex claims within the Veterans Benefits Administration, including how it relates to Military Sexual Trauma and Traumatic Brain Injury. Lobbied against the elimination of Claims Assistant positions across the VBA. Lobbied for the specialization of claims processing for highly complex cases. Lobbied for increased oversight and changes to performance standards for Legal Administrative Assistants in the VBA National Call Centers. Lobbied to support and amend H.R. 7784 the VA Police Improvement and Accountability Act. Lobbied to amend H.R. 8247, the COMPACT Act of 2020. Lobbied to support H.R. 6082, the Forgotten Vietnam Veterans Act. Lobbied for technical changes to S. 524/H.R. 2791, the Department of Veterans Affairs Tribal Advisory Committee Act of 2019. Lobbied for changes to the VA-SBA Act, as it appeared in S. 4520 and the NDAA. Lobbied for changes to H.R. 1615, the Verification Alignment and Service-disabled Business Adjustment Act. Lobbied for changes to S. 805, the Stopping Harm and Implementing Enhanced Lead-Time for Debts for Veterans Act of 2020 or the SHIELD for Veterans Act of 2020. Lobbied to support S. 2950, the Veterans Burn Pits Exposure Recognition Act of 2019. Lobbied against S. 4393, the Toxic Exposure in the American Military Act of 2020, or the TEAM Act of 2020. Lobbied for changes to H.R. 7111, the Veterans Economic Recovery Act of 2020. Lobbied for changes to the VA Website Accessibility Act of 2019, including H.R. 1199, S. 746, S. 3587. Lobbied for changes to H.R. 7105, the DELIVER Act. Lobbied for changes to S. 785, the Commander John Scott Hannon Veterans Mental Health Care Improvement Act on 2019. Lobbied in support of H.R. 1133 and S. 462 to restore full Title 38 collective bargaining rights. Lobbied against Section 501 of S. 785 that would convert VA psychologists from hybrid Title 38 to full Title 38 and lobbied for more recruitment and retention incentives for VA psychologists. Lobbied for Congressional oversight on the VA's behavior during the negotiation of a new collective bargaining agreement. Lobbied on changes to the VA Accountability Act. Lobbied for AIR Act funding moratorium. Lobbied for AIR Act repeal. Lobbied MilCon-VA for staffing language to address vacancies. Lobbied to improve H.R. 3530, the "Improving Confidence in Veterans' Care Act." Specifically, sections on clinician reporting and clear record agreements. Lobbied against S. 1906/H.R. 3495, the "Improve Well-being for Veterans Act" to provide grants to outside groups to provide mental health treatment referrals for mental health treatment and wraparound services to veterans. Lobbied for Representative Takano's "Amendment in the Nature of a Substitute to H.R. 3495" Lobbied against S. 221, the "Department of Veterans Affairs Provider Accountability Act" to report every Title 38 clinician adverse action to national practitioner data bank and state licensing board and prohibit every VA employee from entering into a clear record agreement. Lobbied against H.R. 3996, the "VA Design Build Construction Enhancement Act of 2019" that would force the VA to use the designed build process. Lobbied against H.R. 3995, the "Veterans, Employees, and Taxpayers Protection Act of 2019." Lobbied against S. 1101, the "Better Examiner Standards and Transparency for Veterans Act of 2019." Lobbied against certain provisions in the draft legislation, the Reducing Veteran Homelessness Act of 2020. Lobbied for the expanded use of telework during the COVID-19 Pandemic. Lobbied for a stronger and more transparent Defense Production Act with an expanded stakeholder role for front line employees and their unions, including additional PPE for VA employees at VA Medical Centers and Regional Offices. Lobbied for the presumption that VA Medical Workers who contract COVID-19 did so while on duty. Lobbied for VA Medical Workers to get Pandemic Premium Pay. AFGE provided a Statement for the Record for a Senate Veterans Affairs Committee hearing entitled, VAs Response to COVID-19 across the VA Enterprise on December 9, 2020. Lobbied for changes to H.R. 8275, the Reducing Veteran Homelessness Act of 2020." Lobbied to support H.R. 6141, the Protecting Moms Who Served Act. Lobbied to support S. 514, the Deborah Samson Act. Lobbied to support S. 629, Accountability in Department of Veterans Affairs Scheduling and Consult Management Act. Lobbied for changes to S. 711, CARE for Reservists Act of 2019. Lobbied against S. 3235, Veterans Posttraumatic Growth Act. Lobbied for changes to H.R. 7105, the Johnny Isakson and David P. Roe, M.D. Veterans Health Care and Benefits Improvement Act of 2020. FY 2020 Emergency Supplemental Coronavirus Pandemic Response Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 925, the Heroes Act; H.R. 8015, the Delivering for America Act; and H.R. 8319, the FY 2020 Continuing Appropriations and Other Extensions Act. FY 2020 Supplemental Appropriations - Lobbied for passage of and inclusion of federal workforce provisions in H.R. 8900 making continuing appropriations for FY 2020 through December 18, 2020. Lobbied for passage of H.J.Res. 107, making continuing appropriations for FY 2020 through December 20, 2020; lobbied for passage of H.J.Res. 110, making continuing appropriations for FY 2020 through December 21, 2020; lobbied for passage of H.R. 1520, making continuing appropriations for FY 2020 through December 28, 2020. FY 2021 Omnibus Appropriations, H.R. 133 - Lobbied for passage of and inclusion of emergency coronavirus pandemic response provisions for FY 2021, including hazard pay, presumption of workplace illness for frontline employees who contract Covid-19, an OSHA emergency standard and additional PPE and resources to distribute the vaccine to federal workers.
Client expense: $480,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Air Force, Dept of, Army, Dept of (Corps of Engineers), Army, Dept of (Other), Bureau of Citizenship & Immigration Services (BCIS), Commerce, Dept of (DOC), Defense Commissary Agency, Defense Contract Audit Agency (DCAA), Defense Finance & Accounting Service (DFAS), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Environmental Protection Agency (EPA), Federal Emergency Management Agency (FEMA), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Housing & Urban Development, Dept of (HUD), Interior, Dept of (DOI), Justice, Dept of (DOJ), Labor, Dept of (DOL), Natl Institutes of Health (NIH), Navy, Dept of, Office of Management & Budget (OMB), Office of Personnel Management (OPM), SENATE, Transportation Security Administration (TSA), Transportation, Dept of (DOT), U.S. Coast Guard (USCG), U.S. Customs & Border Protection, U.S. Immigration & Customs Enforcement (ICE), U.S. Marines, Veterans Affairs, Dept of (VA), Voice of America
2020 · fourth_quarter · Health Issues
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
Client expense: $1,090,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
2020 · second_quarter · Pharmacy
S. 3129, Crapo The Lower Costs, More Cures Act HR 19 Walden, the Lower Costs, More Cures Act HR 5444 Underwood, Lower Insulin Costs Now Act HR 5304 Schrader, PBM Transparency in Prescription Drug Costs Act HR 4906, DeGette, Regarding the costs of insulin HR 5442, Porter, regarding drug pricing S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Budget/Appropriations
"H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Divisions M and N "Coronavirus Response and Releif Supplemental Appropriations and additional Coronavirus Response and Relief. "H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Division A - Agriculture Appropriations for Fiscal Year 2021 "Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act: Title I Agriculture Programs: National Institute of Food and Agriculture - Research and Education Activities, Hatch Act, and Agriculture and Food Research Initiative (AFRI); National Institute of Food and Agriculture - Extension Activities, Smith Lever Act. "H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Division - B Commerce-Justice-Science Appropriations for Fiscal Year 2021 "Commerce, Justice, Science and related Agencies Appropriations Act: Title I Department of Commerce: National Oceanic and Atmospheric Administration (NOAA); Title III Science: National Science Foundation (NSF), National Aeronautics and Space Administration (NASA)- Science Mission Directorate, Aeronautics Research Directorate H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Division C Defense Appropriations for Fiscal Year 2021 Defense Appropriations: Title IV Research, Development, Test and Evaluation (Defense-wide): 6.1 Basic Research; Title VI Air Force Research, Development, Test and Evaluation, Applied Research Materials, and Human Effectiveness; Title IV Other Department of Defense Programs: Defense Health Program; Oncology Research Information Exchange Network (ORIEN) "H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Division - D Energy and Water Appropriations for Fiscal Year 2021 "Energy and Water Appropriations: Division D, Title III DOE Energy Programs: Office of Science, Advanced Research Projects Agency - Energy (ARPA-E); Continuing Resolution funding 21st Century Cures Act; FY19: Division A, Title III DOE Energy Programs: Office of Science, Advanced Research Projects Agency - Energy (ARPA-E) H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Division G- Interior Appropriations for Fiscal Year 2021 Interior-Environment Appropriations: Division G, Title I: United States Geological Survey (USGS)- Water Resources Research Institutes (WRRI); Title III: National Endowment for the Humanities (NEH) "H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Division H - Labor - Health and Human Services - Education Appropriations for Fiscal Year 2021 "Labor, Health and Human Services, and Education Appropriations: Title II Department of Health and Human Services (HHS): National Institutes of Health (NIH) and SAMHSA; Title III Department of Education (ED): Pell Grants, Supplemental Educational Opportunity Grant (SEOG), Federal Work Study Program, and International Education Programs "H.R. 133, the FY2021 Omnibus and COVID Relief and Response Act (P.L. 116-260) Division - L Transportation Appropriations for Fiscal Year 2021 "Transportation, Housing and Urban Development, and Related Agencies Appropriations: Division L, Title I Department of Transportation: Office of the Secretary, University Transportation Centers; National Highway Traffic Safety Administration (NHTSA); Operations and Research Highway Safety Research & Development; Autonomous Vehicle Development and Report Language re Designated AV Research Site; FY19: Title I Department of Transportation: Federal Transit Authority "H.R. 8337, FY2021 Continuing Appropriations Resolution (through 12/11/2020) "All provisions H.R. 8900, FY2021 Further Continuing Appropriations Act and Other Extensions Act (through 12/18/2020) All provisions H.J.Res.107, FY2021 Continuing Appropriations Act (through 12/20/2020)All provisions H.J.Res 110, FY2021 Continuing Appropriations Act (through 12/21/2020)All provisions H.R. 1520, FY2021 Continuing Appropriations Act (through 12/28/2020)All provisions H.R.6074/Public Law No: 116-123 - the "Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020"- All provisions H.R. 6201/Public Law No: 116-127, the "Families First Coronavirus Response Act" - Divisions A, C, D, E, F, and G H.R. 748/Public Law No: 116-136, the "Coronavirus Aid, Relief, and Economic Security (CARES) Act" Titles I, II, III, IV, V H.R. 6800, The Heroes ActDivisions A, B,C,K,L,M,O, and S
Client expense: $50,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
H.R. 3502, Protecting People from Surprise Medical Bills Act, all provisions H.R. 5826, Consumer Protections Against Surprise Medical Bills Act of 2020, all provisions H.R. 3630, No Surprises Act, all provisions S. 1895, Lower Health Care Costs Act, provisions relating to surprise billing S. 1531, Stopping The Outrageous Practice of (STOP) Surprise Medical Bills Act of 2019, all provisions S. 4421, Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act, all provisions H.R. 6644, To require group health plans and health insurance issuers offering group or individual health insurance coverage to provide coverage for services furnished via telehealth if such services would be covered if furnished in-person during the COVID-19 emergency, all provisions S. 3741, Health Care at Home Act of 2020, all provisions S. 4666, National Coronavirus Commission Act of 2020, all provisions S. 4507, Getting Early Treatment and Comprehensive Assessments Reduces Emergencies (GET CARE) Act of 2020, all provisions H.R. 8441, Frontline Heroes Act, all provisions S. 4317, SAFE TO WORK Act, all provisions H.R. 925, The Heroes Act, all provisions S. 3749, Public Health Emergency Privacy Act, all provisions S. 3861, Exposure Notification Privacy Act, all provisions H.R. 6585, Equitable Data Collection and Disclosure on COVID-19 Act, all provisions H.R. 7510, Assimilating Health and Equity Assessments into Decision-making (AHEAD Act) of 2020, all provisions S. 4919, Assimilating Health and Equity Assessments into Decision-making (AHEAD Act) of 2020, all provisions H.R. 6808, Health Force and Resilience Force Act of 2020, all provisions S. 3606, Health Force and Resilience Force Act of 2020, all provisions H.R. 7255, Coronavirus Health Care Worker Wellness Act of 2020, all provisions H.R. 8094, Dr. Lorna Breen Health Care Provider Protection Act, all provisions S. 4349, Dr. Lorna Breen Health Care Provider Protection Act, all provisions H.R. 3884, Marijuana Opportunity Reinvestment and Expungement (MORE) Act of 2020, all provisions S. 2032, Cannabidiol and Marihuana Research Expansion Act, all provisions H.R. 1503, Orange Book Transparency Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 1520, Purple Book Continuity Act of 2019, provisions related to PBM and prescription drug price transparency H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act, provisions related to PBM and prescription drug price transparency H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act, provisions related to PBM and prescription drug price transparency H.R. 4995, Maternal Health Quality Improvement Act of 2020, all provisions H.R. 7120, George Floyd Justice in Policing Act of 2020, provisions relating to police reform Affordable Care Act stabilization Expansion of Paycheck Protection Program for 501(c)6s Public Health and Social Services Emergency Fund Marginalized and minoritized communities/COVID-19 disproportionate impact COVID-19 long haulers COVID-19 testing/vaccines/health care prior authorization COVID-19/treatment and prescribing flexibilities COVID-19/Expanded PPE/clearinghouses E/M services Surprise medical billing executive orders Surprise Medical Billing, generally Clinical and administrative data intersection State Medical Boards/Interstate Medical Licensure Compact Pharmacists and COVID-19 testing Mental health parity Digital therapeutics Physician practice financial impact 21st Century Cures Act/health data and privacy 42 CFR Part 2, HIPAA Patent reform CPT - digital Most favored nation drug pricing Drug pricing Health Information Technology/information blocking Dietary guidelines/alcohol consumption Data privacy Cyber security best practices Race and sex stereotyping executive order
Client expense: $3,870,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Bureau of Citizenship & Immigration Services (BCIS), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Emergency Management Agency (FEMA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, Veterans Affairs, Dept of (VA), White House Office
2020 · fourth_quarter · Government Issues
Contacted Congressional officials regarding an upcoming virtual industry exhibit. H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority.
Client expense: Not reported · Firm income: $40,000
Government targets: Air Force, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority. Contacted Congressional officials regarding an upcoming virtual industry exhibit.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority. Contacted Congressional offices regarding an upcoming virtual industry exhibit.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
Contacted Congressional officials regarding an upcoming virtual industry exhibit. Contacted Congressional officials regarding the acquisition of another company. H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority. Contacted Congressional offices regarding an upcoming industry virtual exhibit.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority. Contacted Congressional offices regarding an upcoming virtual industry exhibit.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority. Contacted Congressional officials regarding an upcoming industry exhibit.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Government Issues
Contacted Congressional offices regarding an upcoming event hosted by Battelle regarding national security issues. Contacted Congressional officials regarding an upcoming virtual industry exhibit day. H.R.133 (Consolidated Appropriations Act, 2021, Title X, Sec. 1002) / H.R.8900, H.J.Res.107, H.J.Res.110, H.R.1520 (Continuing Appropriations Acts), All provisions relating to federal contractor authority.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Health Issues
Affordable prescription drugs, 340B Program; HR985 FAST Generics Act of 2019; Appropriate and accurate payment for healthcare; Site Neutral payment policies; S. 1895 - Lower Health Care Costs Act; S. 340 - CREATES Act, H.R. 987 - Strengthening Health Care and Lowering Prescription Drug Costs Act; S. 1391 - Fair Accountability and Innovative Research Drug Pricing Act of 2019; Surprise billing: S. 1531 - Stop the Outrageous Practice of Surprise Medical Bills Act of 2019; HR 3, the Lower Drug Costs Now Act; H.R.2149 - Exposing the Financing of Human Trafficking Act; H.R.508 - Trafficking Victims Housing Act of 2019; H.R. 1520 - Purple Book Continuity At of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; S.2543 - Prescription Drug Pricing Reduction Act of 2019; Health care privacy; patient privacy; H.R. 647, S.2080 - Palliative Care and Hospice Education and Training Act; Conrad 30 and the Physician Access Reauthorization Act, S 948; Issues related to the Medicaid Fiscal Accountability Regulation (MFAR); HR 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act; HR 6201 - Families First Coronavirus Response Act - Public Law No: 116-127; HR 748 - Coronavirus Aid, Relief, and Economic Security (CARES) Act; response to the COVID-19 public health emergency; S. 178 - HEALS Act; H.R. 1425, Patient Protection and Affordable Care Enhancement Act; H.R. 6800 - HEROES Act; H.R. 266, Paycheck Protection Program and Health Care Enhancement Act; issues related to coverage of virtual car; Financial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, and access to PPE and other materials and equipment related to the treatment of patients with COVID-19; H.R. 133 - Consolidated Appropriations Act; Issues related to social determinants of health; H.R. 6561 - Improving Social Determinants of Health Act ; S. 4421- Temporary Reciprocity to Ensure Access to Treatment Act; liability relief for health care providers
Client expense: $290,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), Vice President of the U.S.
2020 · fourth_quarter · Budget/Appropriations
H.R. 6800 - The HEROES Act H.R.7610 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2021 Health, Economic Assistance, Liability Protection, and Schools (HEALS) Act H.R.7608 - State, Foreign Operations, Agriculture, Rural Development, Interior, Environment, Military Construction, and Veterans Affairs Appropriations Act, 2021 H.R.8337 - Continuing Appropriations Act, 2021 and Other Extensions Act H.R.8406 - The Heroes Act H.R.925 - The Heroes Act H.R.8900 - Further Continuing Appropriations Act, 2021, and Other Extensions Act H.J.Res.107 - Further Additional Continuing Appropriations Act, 2021 H.J.Res.110 - Extension of Continuing Appropriations Act, 2021 H.R.1520 - Further Extension of Continuing Appropriations Act, 2021 H.R.133 - Consolidated Appropriations Act, 2021
Client expense: $21,351 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Pharmacy
H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, Prescription Drug STAR Act of 2019; H.R. 2069/S. 474, Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019; H.R. 2296/S. 1391, FAIR Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, More Efficient Tools to Realize Information for Consumers (METRIC) Act of 2019; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 4712, Fairness in Orphan Drug Exclusivity Act.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2020 · fourth_quarter · Health Issues
Lower Health Care Costs Act (S.1895) Reauthorizing and Extending America's Community Health Act - REACH Act (H.R. 2328) Preserve Access to Affordable Generics and Biosimilars Act (S. 64/H.R. 2375) Protecting Jessica Grubbs Legacy Act (S. 1012) Overdose Prevention and Patient Safety Act (H.R. 2062) ACA Medicaid disproportionate share hospital (DSH) cuts Prescription Drug Price Transparency Act (H.R.1035) Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 803) Short on Competition Act (S. 844) Resident Physician Shortage Act of 2019 (H.R. 1763/S. 348) FAST Generics Act (H.R. 985) The Protecting Consumer Access to Generic Drugs Act of 2019 (H.R. 1499) The Fair and Immediate Release of Generic Drugs Act (H.R. 1506) The Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 (H.R. 938) The Orange Book Transparency Act of 2019 (H.R. 1503) The Purple Book Continuity Act of 2019 (H.R. 1520) Home infusion: 50401 of the Bipartisan Budget Act of 2018 (BBA) (Pub. L. 115-123) and section 5012 of the 21st Century Cures Act of 2016 (CURES) (Pub. L. 114-255) Phair Pricing Act (H.R. 1030) Improving Seniors' Timely Access to Care Act of 2019 (H.R. 3107) The Mitigating Emergency Drug Shortages (MEDS) Act (S.2723) Accountable Care in Rural America Act (H.R. 5212) Rural ACO Improvement Act (S.2648) Helping Medicaid Offer Maternity Services (H.R. 4996) Prescription Drug Pricing Reduction Act of 2019 (S. 2543) Stop STALLING Act (H.R. 2374) Reforming Evergreening and Manipulation that Extends Drug Years Act (S. 1209) Preventing Drug Shortages Act (H.R. 6080) Protecting Jessica Grubb's Legacy Act (S. 3374) Preserving Patient Access to Home Infusion Act (H.R. 6218/S. 3457) Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R. 6074) Families First Coronavirus Response Act (H.R. 6201) Coronavirus Aid, Relief, and Economic Security Act (H.R. 748) The HEROES Act (HR 6800)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · fourth_quarter · Transportation
S.713, Highway-Rail Grade Crossing Safety Act of 2019 - bill in its entirety; S. 2979, Preventing Opioid and Drug Impairment in Transportation Act - bill in its entirety; HR. 3409, Coast Guard Authorization Act of 2019 - bill in its entirety; S. 2302, America's Transportation Infrastructure Act of 2019 - bill in its entirety; HR. 5273, Securing America's Ports Act - bill in its entirety; HR. 7904, Critical Infrastructure Employee Protection Act of 2020 - bill in its entirety; S. 3728, Critical Infrastructure Employee Protection Act of 2020 - bill in its entirety; HR. 2, Investing in a New Vision for the Environment and Surface Transportation in America Act - Division A- Sec. 1101; Sec. 1104; Sec. 1204; Sec. 1205; Sec. 1212; Sec. 1301; Sec. 1302; Sec. 6001; Sec. 6002; Sec. 6003; Sec. 6004; Sec. 6005; Sec. 6006; Sec.6007; Sec. 6008; Sec. 6009; Sec. 6010; Sec. 8202; Division D; Sec.1603; Sec. 33301; HR.7095, Investing in a New Vision for the Environment and Surface Transportation in America Act - bill in its entirety; HR. 133, Consolidated Appropriations Act, 2021 - Division G; Division L; Division O, Title VI; HR. 8337, Continuing Appropriations Act, 2021 and Other Extensions Act - Sec. 1103; HR.8900, Further Continuing Appropriations Act, 2021, and Other Extensions Act - Bill in its entirety; HJ. Res 107, Further Additional Continuing Appropriations Act, 2021 - Bill in its entirety; HJ. Res 110, Extension of Continuing Appropriations Act, 2021 - Bill in its entirety; HR. 1520, Stopgap Funding Through Dec. 28, 2020 - Bill in its entirety; Issues related to truck size and weight; Issues related to standard and metrics; Issues related to an implementation plan for truck size and weight research; Issues related to the incorporation of cost-benefit analysis for regulatory action at the Surface Transportation Board; Issues related to a mode-neutral framework for the future regulation of emerging technologies; Issues related to railroad emergency response contractor hours of service; Issues related to FAST Act Reauthorization; Issues Related to CDC Guidance for critical infrastructure employees; Issues related to Rail Safety Week; Issues related to the Surface Transportation Board and their nominations; Issues related to the Railroad Retirement Board; Issues related to autonomous vehicles.
Client expense: $1,113,790 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Environmental Protection Agency (EPA), Federal Aviation Administration (FAA), Federal Railroad Administration, HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Pipeline & Hazardous Materials Safety Administration, SENATE, Transportation, Dept of (DOT), White House Office
2020 · fourth_quarter · Health Issues
Support HR 1763/ S 348, Resident Physician Shortage Reduction Act of 2019, a bill to amend title XVIII of the Social Security Act to provide for the distribution of additional residency positions; Oppose HR 506,Hospital Competition Act of 2019, a bill to amend title XVIII of the Social Security Act to increase hospital competition; Statement submitted to the House Judiciary on the hearing "Diagnosing the Problem: Exploring the Effects of Consolidation and Anticompetitive Conduct in Health Care Markets"; Support HR 965/ S340, Creating and Restoring Equal Access to Equivalent Samples Act of 2019 or the CREATES Act of 2019, a bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products; Support HR 986/ S466 Protecting Americans with Preexisting Conditions Act of 2019, a bill provide that certain guidance related to waivers for State innovation under the Patient Protection and Affordable Care Act shall have no force or effect; Support HR 987 Strengthening Health Care and Lowering Prescription Drug Costs Act, a bill to amend the Patient Protection and Affordable Care Act to provide for Federal Exchange outreach and educational activities; Support HR 938 Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 or the BLOCKING Act of 2019, a bill to amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes; Support HR 1010, a bill to provide that the rule entitled Short-Term, Limited Duration Insurance shall have no force or effect; Support HR 1499 Protecting Consumer Access to Generic Drugs Act of 2019, a bill to prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes; Support HR 1425 State Health Care Premium Reduction Act, a bill to amend the Patient Protection and Affordable Care Act to provide for a Improve Health Insurance Affordability Fund to provide for certain reinsurance payments to lower premiums in the individual health insurance market; Support HR 1386/ S 1905 Expand Navigators Resources for Outreach, Learning, and Longevity Act of 2019 or the ENROLL Act of 2019,a bill to amend the Patient Protection and Affordable Care Act to provide for additional requirements with respect to the navigator program, and for other purposes; Support HR 1520 Purple Book Continuity Act of 2019, a bill to amend the Public Health Service Act to provide for the publication of a list of licensed biological products, and for other purposes; Support HR 1503 Orange Book Transparency Act of 2019A bill that would increase transparency for the patent status of both approved biological products and approved drugs; Support HR 2439/ HR 3414 Opioid Workforce Act of 2019, a bill to amend title XVIII of the Social Security Act to provide for the distribution of additional residency positions to help combat the opioid crisis; Submitted statement to the House Committee on Ways and Means Overcoming Racial Disparities and Social Determinants in the Maternal Mortality Crisis sharing information regarding hospitals and health systems efforts to address maternal morbidity and mortality, as we seek ways to improve outcomes and reduce health inequities for expectant and new mothers, and give their children the best possible start in life; Submitted oral and written testimony to the House Committee on Ways and Means Subcommittee on Health Hearing on Protecting Patients from Surprise Medical Bills. Protecting patients from surprise medical bills is a top priority and we have adopted a set of guiding principles to use as we evaluate legislative proposals: Define surprise bills, Protect the patient financially, Ensure patient access to emergency care, Preserve the role of private negotiation, Remove the patient from health plan/provider negotiations, Educate patients about their health care coverage, Ensure patients have access to comprehensive provider networks and accurate network information, and Support state laws that work; Letters submitted to the Energy & Commerce Committee in response to the request for comments on their surprise billing discussion draft. Concerned with the Committees draft legislations approach to determining reimbursement for out-of-network providers. Once the patient is protected from surprise bills, providers and insurers should then be permitted to negotiate payment rates for services provided. We strongly oppose approaches that would impose arbitrary rates on providers. We look forward to continuing to work with the Committee on solutions to stop surprise medical bills; Letter sent to the HELP Committee in response to the Lower Health Care Costs Act of 2019 discussion draft about our concerns about several of the proposals that would allow the government to intrude into private commercial contracts between providers and insurers. For example, several of the provisions could undermine value-based purchasing arrangements aimed directly at improving the quality of care while reducing costs. We strongly urge the Committee to remove these provisions; Submitted oral and written testimony to the House Committee on Energy and Commerce, Subcommittee on Health Hearing on No More Surprises: Protecting Patients from Surprise Medical Bills asking that the Committee preserve the ability of providers and insurers to negotiate private contracts and not establish a fixed payment amount for out-of-network services; Oppose HR 1309 Workplace Violence Prevention for Health Care and Social Service Workers Act, a bill to direct the Secretary of Labor to issue an occupational safety and health standard that requires covered employers within the health care and social service industries to develop and implement a comprehensive workplace violence prevention plan, and for other purposes; Concerns about S.1531, Stopping The Outrageous Practice of Surprise Medical Bills Act of 2019 or the STOP Surprise Medical Bills Act of 2019, to amend the Public Health Service Act to provide protections for health insurance consumers from surprise billing; Concerns about S. 1895 Lower Health Care Costs Act Letter addressed concerns about the legislative provision that sets a benchmark rate in statute for the out-of-network payments, as well as provisions that seek to change privately negotiated contracting arrangements between hospitals and insurance companies; Support HR 3425, Advancing Medical Resident Training in Community Hospitals Act of 2019, to amend title XVIII of the Social Security Act to establish rules for payment for graduate medical education (GME) costs for hospitals that establish a new medical residency training program after hosting resident rotators for short durations; Expressed concerns regarding the provisions that reduce reimbursements to providers and hospitals that administer drugs the Prescription Drug Pricing Reduction Act (PDPRA) of 2019: including about Section 107, Medicare Part B Rebate by Manufacturers for Drugs or Biologicals with Prices Increasing Faster than Inflation, Section 110, Establishment of Maximum Add-on Payment for Drugs, Biologicals, and Biosimilars, this provision would establish $1,000 as the maximum add-on amount that a provider can be paid for a separately payable drug, biological or biosimilar, Section 111, Treatment of Drug Administration Services Furnished by an Off-Campus Outpatient Department of a Provider, the site neutral payment reduction would cut aggregate hospital payments; Support S. 2091, Backlog Elimination, Legal Immigration, and Employment Visa Enhancement Act, this legislation would increase the total number of employment-based visas from 140,000 to 270,000 and ensure that critical health care workers needed in the U.S. have access to employment-based visas by carving out health care workers in designated shortage occupations from the limit; Support S 350, The Competitive Health Insurance Reform Act of 2019, a bill to restore the application of the Federal antitrust laws to the business of health insurance to protect competition and consumers; Submitted statement to Subcommittee on Health of the Committee on Energy and Commerce for the hearing on Improving Maternal Health: Legislation to Advance Prevention Efforts and Access to Care; Concerns with S. 386 and HR 1044, Fairness for High-Skilled Immigrants Act of 2019, this bill increases the per-country cap on family-based immigrant visas from 7% of the total number of such visas available that year to 15%, and eliminates the 7% cap for employment-based immigrant visas. It also removes an offset that reduced the number of visas for individuals from China; Support H.R. 4538, Closing Loopholes for Orphan Drugs Act, a bill to amend title III of the Public Health Service Act to limit the orphan drug exclusion under the drug discount program under section 340B of such title; Discussions of provisions we support and those we recommend be changes in a draft bill called the Mitigating Existing Drug Shortages (MEDS) Act; Discussions in support of the allowing states to designate hospitals as necessary providers for purposes of waiving the critical access hospital mileage requirements; Provided comments to W&M on legislation to expand Health Profession Opportunity Grants; Support S. 2723, The Mitigating Emergency Drug Shortages (MEDS) Act, a bill to amend Sec. 506C of the Federal Food, Drug, and Cosmetic Act which strengthens requirements for drug manufacturers to disclose the root causes and expected duration of shortages, extends reporting requirements to active pharmaceutical ingredients manufacturers, requires manufacturers have contingency plans to ensure ongoing supply, develops recommendations to incentivize manufacturers to enter the market for drugs in shortage and examines the national security risks of shortages; Discuss DEA reductions in annual quotas for opioid products used by hospitals for sedation and pain management; Meeting with the Office of the Assistant Secretary of Preparedness and Response (ASPR) to discuss developments in the hospital preparedness program, the pilot projects for the Regional Disaster Healthcare System and other issues; Rural access to health care, including identifying core services needed in rural communities, outlining approaches and considerations for delivering those services, and examining access and quality in the rural context; ONCs proposed rule to implement the 21st Century Cures provision on information blocking; Supported members serving on the HHS Quality Summit panel, which was convened by the Deputy Secretary to gather input regarding how to improve and energize quality and safety improvement activities across health care system; Discussion with HHS on drug pricing, 340b, and price transparency policies, as well as the International Pricing Index ANPRM; Discussion with HHS about the work of Aligning for Health to address social determinants of health; Support S 2902, Strengthening Our Rural Health Workforce Act of 2019, a bill to enhance the rural health workforce; Meetings and correspondence with staff members of Senate Financing Committee on a proposal to support rural health care access (REH, re-opening necessary provider CAH, infrastructure funding); Letter to Ways & Means committee Rural and Underserved Communities Health Task Force in response to RFI on factors that contribute to health outcomes in these areas, examples of successful models and lessons from the field that address access and outcomes, and considerations for the unique circumstances of rural and underserved communities; Letter to Energy and Commerce Members regarding health information technology priorities; Letter of Support to Senate Appropriations on funding for the Centers for Disease Control and Prevention and the National Institutes of Health to study gun violence; Support S.2741 and H.R. 4932,Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2019, a bill to amend title XVIII of the Social Security Act to expand access to telehealth services, and for other purposes; Support S 2603, Resolving Extended Limbo for Immigrant Employees and Families (RELIEF) Act, a bill to amend the Immigration and Nationality Act to end the immigrant visa backlog, and for other purposes; Support HR 4995, Maternal Health Quality Improvement Act of 2019, a bill to amend the Public Health Service Act to improve obstetric care and maternal health outcomes, and for other purposes; Concerns with HR 5800,Ban Surprise Billing Act, a bill to address surprise medical bills that relies on a median in-network rate to resolve out-of-network payments and allows for an independent dispute resolution process to determine the final payment. Concerned with the Committee's legislative approach to determining reimbursement for out-of-network providers. Oppose approaches that would impose arbitrary rates on providers, which could have significant consequences far beyond the scope of surprise medical bills. It is the insurers' responsibility to maintain comprehensive provider networks, and a default payment rate would remove incentives for health plans to contract with providers or to offer fair terms; Support HR 5826, Consumer Protections Against Surprise Medical Bills Act, a bill that prohibits providers from balance billing patients for emergency services or medical care the patient reasonably could have expected to be in-network, and from charging patients more than the in-network cost-sharing amount. Rather than rely on a benchmark payment rate to determine out-of-network reimbursement, the legislation provides a period for health plans and providers to negotiate out-of-network reimbursement, followed by a mediated dispute resolution process if necessary; Letter urging HHS to take regulatory actions to help hospitals and health systems prepare and respond to COVID-19; Letter requesting $100 billion to prepare and respond to COVID-19; Letter urging the Department of Labor to accurately define health care provider when promulgating regulations implementing key sections of the Families First Coronavirus Response Act; Letter sent to the President asking for the use of the Defense Production Act to increase the production of medical supplies and equipment; Letter to HHS regarding $100 billion emergency fund, asking HHS and CMS to directly and expediently distribute to rural and urban hospitals and health systems funds from the Public Health and Social Services Emergency Fund that were designated for providers in the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The CARES Act increased funding by $100 billion in order to reimburse eligible health care providers for health care-related expenses or lost revenues that are attributable to COVID-19. In the letter, we urged HHS and CMS to immediately distribute funding to all hospital types in the US - with additional funding going to COVID-19 hotspots; Letter urging Congress to modernize the Stafford Act as part of its next COVID-19 legislative package to allow all hospitals to recoup financial losses from this pandemic and future disasters; Letter to the Federal Reserve System, the Federal Deposit Insurance Corporation and the Office of the Comptroller of the Currency requesting they, as primary federal regulators for insured depository institutions, take prompt action to assist health care providers on the front line of the COVID-19 pandemic should the need to do so arise; Letter to the Secretary of the Treasury and the Federal Reserve Chair of the Board of Governors urging a supplement to the New Main Street Loan Facility term sheet with prompt guidance to ensure that access to this critically-necessary loan facility will be attainable for hospitals without delay; Letter was sent to the SBA urging it to ensure that small- and mid-size public hospitals, including those that have both nonprofit and public designations, are allowed to apply for and receive loans under the newly-authorized SBA Paycheck Protection Program; Letter in response to FEMAs request for input on establishing a voluntary agreement, under the Defense Production Act, of key private sector stakeholders relevant to responding to COVID-19, urging that such an agreement account for the full breadth of COVID-19 medical supply and equipment needs; Support H.R. 6474/S.3838 Healthcare Broadband Expansion During COVID-19 Act, a bill that would provide an additional $2 billion in funding for the FCC Rural Health Care program and increase the subsidy for health care providers from 65 to 85 percent. This legislation also simplifies the program to allow for more efficient application processes and disbursement of much needed funding; Support HR 6654 Emergency COVID-19 Telehealth Response Act, a bill that would codify an expanded list of providers to deliver and bill for telehealth services during the PHE; Support HR 7233Knowing the Efficiency and Efficacy of Permanent (KEEP) Telehealth Options Act of 2020, a bill that would require the Department of Health and Human Services and the Government Accountability Office (GAO) to conduct studies to provide information about the expanded use of telehealth during the COVID-19 pandemic; Letter to Senate HELP Committee in response to request for feedback on preparing for next pandemic; Discussion about telehealth waivers and flexibilities with HHS; Discussion about CARES provider relief fund distributions with HHS; Oppose HR 6559/ S 3677 COVID-19 Every Worker Protection Act of 2020, a bill to require the Occupational Safety and Health Administration to promulgate an emergency temporary standard to protect employees from occupational exposure to SARS-CoV-2, and for other purposes; Joint letter with ANA urging Congress to act quickly to get needed resources into the health care system, so that hospitals, nurses and physicians responding to COVID-19 are able to continue to provide treatments, front-line health care personnel are able to provide care and patients are able access health care services; Statement to Committee on Ways and Means for the hearing on The Disproportionate Impact of COVID-19 on Communities of Color urging Congress to employ the resources of the National Institute on Minority Health and Health Disparities - which is congressionally-mandated to coordinate the research of the other National Institutes of Healths centers and institutes related to minority health - to research and develop approaches to specifically address the COVID-19 needs of minority populations; Advocate with Congress for full forgiveness of COVID-19 related accelerated payments received by hospitals; Support S 3781Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act, a bill to increase reporting of, help mitigate potential shortages related to, and promote, accountability and transparency for pharmaceuticals and medical devices; Support S 3780 Help Onshore Manufacturing Efficiencies (HOME) for Drugs and Devices Act, a bill to encourage domestic advanced manufacturing of critical drugs and devices in order to address economic, health, and security concerns, combat shortages of critical drugs and devices, and promote increased domestic diversification of, and independence from foreign reliance on, pharmaceutical and medical device supply chains; Support S.3763 Pandemic Responder Service Award Act, a bill to establish the Pandemic Responder Service Award program to express our gratitude to front-line health care workers; Support HR 6788/ S 3599 Healthcare Workforce Resilience Act, a bill to enhance our Nations nurse and physician workforce during the COVID-19 crisis by recapturing unused immigrant visas; Urged support for joint House and Senate letter to the Administration asking for flexibility for hospitals with respect to J-1 and H-1B visa programs; Letter to Senate Finance Committee to address the important issue of maternal health and the opportunity to provide suggestions regarding how to improve maternal health in this country; Support the Temporary Reciprocity to Ensure Access to Treatment Act, a bill that allows for the temporary reciprocity for treatment by medical professionals licensed in one state to patients in other states; Letter urging the Senate to include in the next COVID-19 relief bill provisions to strengthen the federal response for racial and ethnic minority and marginalized communities, which are disproportionately affected by the pandemic;Letter asking Congress to allocate as part of the next COVID-19 relief package at least an additional $100 billion to the emergency relief fund to provide direct funding to front line health care personnel and providers to continue to respond to this pandemic; Letter sent to HHS urging them to direct HRSA to take action to stop three drug manufacturers from limiting the distribution of 340B drugs to 340B covered entities. These drug manufacturers have taken separate actions to either limit the distribution of 340B drugs or require 340B covered entities provide claims level data for investigatory purposes if that 340B covered entity uses a contract pharmacy arrangement; Letter to the Congressional Leadership asking them to not to include in the next COVID-19 relief package any surprise medical billing legislation - such as a reimbursement rate set in statute - that would further destabilize hospitals finances during the pandemic; Support S 4507, Getting Early Treatment and Comprehensive Assessments Reduces Emergencies Act of 2020 or the GET CARE Act of 2020, a bill to amend the Public Health Service Act to provide for a national campaign to raise awareness of the importance of seeking preventive health services and the utilization of such services; Comment letter addressing concerns on the proposed rule from the Departments of the Treasury, Labor and Health and Human Services that would allow certain grandfathered health plans to increase patient cost-sharing beyond current limits, without losing their grandfathered status; Letter urging the Administration to work with the AHA and Congress to create a future for telehealth that allows not only clinicians, but also hospitals and health systems, to code and bill for virtual services. We further urge CMS and HHS to continue to provide hospitals with the flexibility for annual beneficiary consent to telehealth treatment to be obtained at the same time, and not necessarily before, services are furnished; Support HR 8061,Community Immunity During COVID-19 Act of 2020, a bill that would provide funding to state and local health departments to work with community providers and organizations to increase immunization rates for Advisory Committee on Immunization Practices (ACIP)-recommended vaccines during the COVID-19 public health emergency; Letter again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members. While we understand that the HRSA is further investigating these actions, we urge swift and decisive action to halt these pernicious tactics so as to prevent other manufacturers from following suit; Comment letter outlining our concerns about the ability of hospital systems to distribute provider relief funds among the parent and subsidiaries. HHS published certain FAQs that place problematic restrictions on the use of CARES Act provider relief fund dollars. Specifically, the FAQs restrict the ability of a hospital system to allocate the funds throughout its system where COVID-19 related expenses and lost revenues are occurring; Submitted comments in response to HRSAs RFI on Health Professional Shortage Area (HPSA) scoring. HPSA scores are important for rural hospitals and clinics ability to recruit physicians and other clinicians, namely from the National Health Service Corps (NHSC) program. Letter asking HHS to reinstate the COVID-19 Provider Relief Fund reporting requirements; Support S 4349, Dr. Lorna Breen Health Care Provider Protection Act, a bill to address behavioral health and well-being among health care professionals; Support S. 3595Ensuring Understanding of COVID-19 to Protect Public Health Act, a bill that directs the NIH to conduct a longitudinal study on mild, moderate, and severe cases of COVID-19 on a diverse patient population.
Client expense: $4,460,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Veterans Affairs, Dept of (VA), White House Office